<i>EGFR-V834L</i> combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer.

ABSTRACT:

Background

The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is widely used as a first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC). However, there is no established treatment for osimertinib resistance, so second-generation afatinib is an alternative treatment option. The purpose of this study was to elucidate gene alterations associated with afatinib efficacy and resistance by analyzing cell-free DNA (cfDNA) obtained from patients with EGFR-mutated NSCLC.

Methods

This study was conducted as a prospective clinical trial in patients with EGFR-mutated NSCLC at multiple institutions. We analyzed plasma cfDNA from the patients treated with afatinib as the first-line therapy.

Res

SUBMITTER: Terada N 

PROVIDER: S-EPMC11632430 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature